Association between non-alcoholic fatty liver disease and incidence of arrhythmia and other cardiovascular outcomes: a systematic review and meta-analysis

Abstract

Funding Acknowledgements Type of funding sources: None. Background The association between non-alcoholic fatty liver disease (NAFLD) with cardiovascular and cerebrovascular outcomes, as well as their clinical impact, has yet to be established in the literature. Objective We aim to evaluate the association between NAFLD patients and the risk of atrial fibrillation (AF), heart failure (HF),stroke, cardiovascular mortality (CVM), and peripheral revascularization. Method We performed a systematic literature search using the PubMed, Embase, Scopus, and Cochrane libraries for relevant articles from inception until July 20th, 2022. Odds ratios (OR) were pooled using a random-effect model, and a p-value of <0.05 was considered statistically significant. Results A total of 10 studies with 17886340 patients (2887214 NAFLD vs 14999126 non-NAFLD) were included in our analysis. The average age and percentage of males were comparable between groups, with a mean age of 55 years and 72.5% of males in the NAFLD group, whereas 52 years and 47.4% of males in the non-NAFLD group. The most common comorbidities among the NAFLD group included: hypertension (38% vs 24%), diabetes mellitus (14% vs 8%). The mean follow-up duration was 6.26 years. The likelihood of atrial fibrillation [OR, 1.42(95%CI: 1.18-1.70), P<0.001], heart failure [OR, 1.48(95%CI: 1.27-1.73), P<0.001], stroke (OR, 1.26(95%CI: 1.17-1.36), P<0.001], and peripheral revascularization (OR, 3.95(95%CI: 1.60-9.73), P=0.003] was significantly higher in NAFLD patients when compared with non-NAFLD patients. In contrast, cardiovascular mortality was comparable between both the groups of patients [OR, 3.11(95%CI: 0.32-30.03), P=0.33] respectively. Conclusion Patients with NAFLD demonstrated increased incidence of cardiovascular and/or cerebrovascular outcomes; heart failure, stroke, and arrhythmia. Patients with associated comorbidities were at higher risk of cardiovascular disease, implying a greater need for screening and adoption of cardio-protective measures amongst NAFLD patients.

Association between rheumatoid arthritis and atrial fibrillation: A systematic review and meta‐analysis

“…This meta‐analysis was conducted and reported following the Cochrane and PRISMA (Preferred Reporting Items for Systematic Review and Meta‐analysis) 2020 guidelines and performed according to established methods, as described previously 15–17 . The pre‐specified study protocol has been registered in the PROSPERO (CRD42023424652).…”

Effect of statin treatment on the risk of cancer in patients with heart failure: A target trial emulation study

“…Cancer and heart failure (HF) are two major causes of morbidity and mortality with a complex inter‐relationship including shared risk factors and overlapping pathophysiology 12,13 . Epidemiological research has shown that the cancer incidence is higher in patients with HF than the general population even after controlling for other risk factors 14 . Given the impact on survival of newer pharmacological treatment for HF, it is of increasing clinical interest to identify strategies to reduce the burden of comorbid cancer in this population 12 .…”